Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 155.-. (canceled)56. A method for treating a lung of a patient , comprising:advancing a catheter into a region of a patient's lung;mixing outside of the lung a first solution comprising a non-natural polymer with a second solution comprising a cross-linker, thereby initiating crosslinking to form a hydrogel;mixing outside of the lung the hydrogel with a gas to form a hydrogel foam; anddelivering the hydrogel foam through the catheter to the region of the lung;wherein crosslinking of the hydrogel foam is completed at the region of the lung.57. The method of claim 56 , wherein the hydrogel foam causes lung volume reduction.58. The method of claim 56 , wherein crosslinking of the hydrogel foam is completed at the region of the lung less than 10 minutes after initiating crosslinking of the hydrogel.59. The method of claim 56 , wherein crosslinking of the hydrogel foam is completed at the region of the lung between 1 and 5 minutes after initiating crosslinking of the hydrogel.60. The method of claim 56 , wherein crosslinking ...

Lung volume reduction therapy using crosslinked non-natural polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 142-. (canceled)43. A method of sealing a bronchopleural fistula in a patient , comprising the step of administering to a patient in need thereof a therapeutically effective amount of a hydrogel , wherein said hydrogel is prepared from(a) a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; and said first cross-linker comprises at least two pendant first electrophilic groups; or(b) a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; and said second cross-linker comprises at least two pendant second nucleophilic groups,thereby sealing said bronchopleural fistula.44. The method of claim 43 , wherein said hydrogel is administered using a bronchoscope.45. The method of claim 43 , wherein said hydrogel is administered using a catheter.4648-. (canceled)49. A method of sealing an air leak in a lung claim 43 , comprising the step of administering to ...

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 149-. (canceled)50. A method of attaching a first tissue to a second tissue of a patient in need thereof , comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel , wherein said hydrogel is prepared from(a) a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; and said first cross-linker comprises at least two pendant first electrophilic groups; or(b) a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; and said second cross-linker comprises at least two pendant second nucleophilic groups,thereby attaching said first tissue to said second tissue.5155-. (canceled)56. The method of claim 50 , wherein said hydrogel is prepared from a first non-natural polymer and a first cross-linker; and said first nucleophilic groups are selected from the group consisting of alcohols claim 50 , amines ...

Lung Volume Reduction Therapy Using Crosslinked Biopolymers

One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels.

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

Tissue volume reduction

Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.

REDUCTION OF TISSUE VOLUME.

Uso de una composición fisiológicamente aceptable que comprende fibrina, monómero de fibrina, o fibrinógeno y un activador de fibrinógeno para la elaboración de un medicamento para su uso en la adhesión de una parte de una zona colapsada de un pulmón a otra en el transcurso de un procedimiento de reducción de volumen pulmonar no quirúrgico.

Lung volume reduction therapy using crosslinked non-natural polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

Use of fibrin or fibrinogen for reducing lung tissue volume

Devices, compositions, and methods comprising fibrin or fibrinogen for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.

Prosthetic device for respiratory patients

The present invention is directed to a prosthetic device that can be implanted in the pleural cavity of patients undergoing lung volume reduction surgery. The device is designed so that its volume can be adjusted by externally adding or removing gas without the need for additional surgical intervention.

Use of fibrin or fibrinogen for reducing lung tissue volume

Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.

Tissue volume reduction

Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.

Lung volume reduction therapy using crosslinked non-natural polymers

One aspect of the invention relates to a hydrogel comprising a nonnatural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogen comprising a non natural polymer comprising a plurality of pendant electrophilic groups and reducing lung volume in a patient comprising the step of administering a hydrogen composition as described herein, Further., hydrogeLs of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a Ling, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

Lung volume reduction therapy using crosslinked non-natural polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

Reduktion af vævsvolumen

Lung volume reduction therapy using crosslinked non-natural polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.